South Korea · Delayed Price · Currency is KRW HYUNDAI BIOLAND Statistics
Total Valuation
HYUNDAI BIOLAND has a market cap or net worth of KRW 120.30 billion. The enterprise value is 107.48 billion.
| Market Cap | 120.30B |
| Enterprise Value | 107.48B |
Important Dates
The next estimated earnings date is Thursday, April 30, 2026.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | Apr 2, 2026 |
Share Statistics
HYUNDAI BIOLAND has 30.00 million shares outstanding.
| Current Share Class | 30.00M |
| Shares Outstanding | 30.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.87% |
| Float | 19.50M |
Valuation Ratios
The trailing PE ratio is 10.43.
| PE Ratio | 10.43 |
| Forward PE | n/a |
| PS Ratio | 0.92 |
| PB Ratio | 0.88 |
| P/TBV Ratio | 0.90 |
| P/FCF Ratio | 7.77 |
| P/OCF Ratio | 6.18 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.09, with an EV/FCF ratio of 6.94.
| EV / Earnings | 425.46 |
| EV / Sales | 0.82 |
| EV / EBITDA | 6.09 |
| EV / EBIT | 8.43 |
| EV / FCF | 6.94 |
Financial Position
The company has a current ratio of 3.26, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.26 |
| Quick Ratio | 1.37 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.59 |
| Debt / FCF | 0.67 |
| Interest Coverage | 27.13 |
Financial Efficiency
Return on equity (ROE) is 8.41% and return on invested capital (ROIC) is 9.53%.
| Return on Equity (ROE) | 8.41% |
| Return on Assets (ROA) | 4.41% |
| Return on Invested Capital (ROIC) | 9.53% |
| Return on Capital Employed (ROCE) | 9.20% |
| Weighted Average Cost of Capital (WACC) | 8.50% |
| Revenue Per Employee | 382.71M |
| Profits Per Employee | 740,825 |
| Employee Count | 341 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 1.40 |
Taxes
In the past 12 months, HYUNDAI BIOLAND has paid 817.77 million in taxes.
| Income Tax | 817.77M |
| Effective Tax Rate | 6.62% |
Stock Price Statistics
The stock price has decreased by -1.90% in the last 52 weeks. The beta is 0.84, so HYUNDAI BIOLAND's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | -1.90% |
| 50-Day Moving Average | 4,239.30 |
| 200-Day Moving Average | 4,554.98 |
| Relative Strength Index (RSI) | 51.92 |
| Average Volume (20 Days) | 63,485 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HYUNDAI BIOLAND had revenue of KRW 130.51 billion and earned 252.62 million in profits. Earnings per share was 8.42.
| Revenue | 130.51B |
| Gross Profit | 53.41B |
| Operating Income | 12.76B |
| Pretax Income | 12.35B |
| Net Income | 252.62M |
| EBITDA | 17.63B |
| EBIT | 12.76B |
| Earnings Per Share (EPS) | 8.42 |
Balance Sheet
The company has 23.25 billion in cash and 10.43 billion in debt, with a net cash position of 12.82 billion or 427.34 per share.
| Cash & Cash Equivalents | 23.25B |
| Total Debt | 10.43B |
| Net Cash | 12.82B |
| Net Cash Per Share | 427.34 |
| Equity (Book Value) | 136.15B |
| Book Value Per Share | 4,538.22 |
| Working Capital | 63.89B |
Cash Flow
In the last 12 months, operating cash flow was 19.48 billion and capital expenditures -4.00 billion, giving a free cash flow of 15.48 billion.
| Operating Cash Flow | 19.48B |
| Capital Expenditures | -4.00B |
| Depreciation & Amortization | 4.88B |
| Net Borrowing | -25.24B |
| Free Cash Flow | 15.48B |
| FCF Per Share | 515.99 |
Margins
Gross margin is 40.93%, with operating and profit margins of 9.77% and 0.19%.
| Gross Margin | 40.93% |
| Operating Margin | 9.77% |
| Pretax Margin | 9.46% |
| Profit Margin | 0.19% |
| EBITDA Margin | 13.51% |
| EBIT Margin | 9.77% |
| FCF Margin | 11.86% |
Dividends & Yields
This stock pays an annual dividend of 35.00, which amounts to a dividend yield of 0.85%.
| Dividend Per Share | 35.00 |
| Dividend Yield | 0.85% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 831.28% |
| Buyback Yield | n/a |
| Shareholder Yield | 0.85% |
| Earnings Yield | 0.21% |
| FCF Yield | 12.87% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 17, 2024. It was a forward split with a ratio of 2.
| Last Split Date | May 17, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
HYUNDAI BIOLAND has an Altman Z-Score of 5.12 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.12 |
| Piotroski F-Score | 6 |